Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation
- PMID: 30337597
- PMCID: PMC6193966
- DOI: 10.1038/s41598-018-33735-x
Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation
Abstract
Children in developing countries are frequently exposed to the pneumococcus, but few develop invasive pneumococcal disease (IPD). We test the hypothesis that natural variation exists in the rapidity of IgG responses following exposure to pneumococcal polysaccharides, and that these differences are sufficiently great to affect susceptibility to and outcome of IPD. We recruited children aged 24-36 months, who had recovered from IPD, and age-matched healthy controls and vaccinated them with 1 dose of the 23-valent PPV to mimic natural exposure. We collected serum samples after vaccination and analysed the dynamics of anti-polysaccharide antibody responses to several capsular antigens. Mean IgG response times to different serotypes were 6.4-7.3 days, with standard deviations of 0.9-1.85 days, suggesting a natural range in response times of up to 7 days. Serotype 1 elicited the largest fold-rise, serotype 23F the smallest. The proportion of responses achieved by day 7 was similar in children with a history of IPD and healthy children. There was considerable natural variation in the rapidity of anti-capsular IgG responses extending over 4-7 days. There was no evidence to suggest that children who have experienced IPD respond more slowly to heterologous pneumococcal capsular antigens than do healthy children.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Hyporesponsiveness to the infecting serotype after vaccination of children with seven-valent pneumococcal conjugate vaccine following invasive pneumococcal disease.Vaccine. 2014 Mar 14;32(13):1444-50. doi: 10.1016/j.vaccine.2014.01.031. Epub 2014 Jan 29. Vaccine. 2014. PMID: 24486367
-
Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.Vaccine. 2014 Jun 30;32(31):4006-11. doi: 10.1016/j.vaccine.2014.04.027. Epub 2014 May 14. Vaccine. 2014. PMID: 24837505
-
The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.Vaccine. 2011 Aug 11;29(35):5886-91. doi: 10.1016/j.vaccine.2011.06.072. Epub 2011 Jul 3. Vaccine. 2011. PMID: 21729732 Clinical Trial.
-
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Clin Microbiol Infect. 2013. PMID: 24083785 Review.
-
Pneumococcal serotype evolution in Western Europe.BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. BMC Infect Dis. 2015. PMID: 26468008 Free PMC article. Review.
References
-
- Pourpak Z, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006;39:114–120. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical